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measured at 0.5, 1, 3, 6 and 12 hours after the start of study drug. The primary end-
point was PCWP at 1 h. Adverse events were monitored through study day 3, and
mortality was assessed through a month.
Results: 93 patients were randomized to rhANP group and 28 to the placebo group at
a ratio of 3:1 using block of size 4. Baseline characteristics were similar among
patients in the study groups, and PCWP were 23.717.0 and 25.668.78 mmHg in
rhANP and placebo group, respectively (P¼0.226). The mean reduction in PCWP was
greater with rhANP (-5.45 mmHg) than placebo (-2.03 mmHg) at 30 minutes, and
there was signiﬁcant difference for the mean PCWP between groups (P¼0.002).
The maximum decrease of PCWP in rhANP group was observed at 1 h (-7.74 vs
-1.82 mmHg with placebo), and the mean PCWP of the two groups were signiﬁcantly
different (P<0.001). At 3 h, PWCP was sustainedly lower in rhANP group
(19.526.55 mmHg) than in placebo group (24.798.42 mmHg) (P<0.001). How-
ever, no signiﬁcant differences were found between the two groups for PCWP at
6 hours (21.436.51 and 24.7910.64 mmHg, P¼0.125). The rate of hypotension
and other adverse event were even in the two groups (P¼0.111).
Conclusions: The short-term infusion of rhANP has prompt hemodynamic
improvement in patients with congestive heart failure compared to placebo added to
standard care.
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Testosterone suppresses ventricular remodeling and improves left ventricular
function in rats following myocardial infarction
Wang Xiaofei, Qu Xingqian, Zhang Tiantian, Zhang Junfeng
Third People’s Hospital, School of Medicine, Shanghai Jiao Tong University
Objectives: To investigate the effects of testosterone on heart function, cardiomyocyte
apoptosis, and ventricular remodeling in male rats post-myocardial infarction.
Methods: Eighty-six male rats were randomly assigned to undergo ligation of the
coronary artery (n¼70) or pseudo surgery (PS, n¼16). Six weeks later, a left ven-
tricular ejection fraction (LVEF) of 45% or less was deﬁned as a successful model of
CHF All model rats were randomly divided into 3 groups: low-dose testosterone (TU),
high-dose TU, and placebo (PL) group. After treatment for 12 weeks, the expression
of several mRNA transcripts in myocardial tissue was measured by real-time PCR.
Immunoﬂuorescence was used to measure myocardial caspase-3 expression.
Results: Compared with the PL group, TU treatment signiﬁcantly improved the
LVEF. Moreover, the mRNA expression of atrial natriuretic peptide (ANP), braim
natriuretic peptide (BNP), matrix metalloproteinase-2 (MMP-2), and sarco/endo-
plasmic reticulum Ca2+-ATPase 2a (SERCA2a) was signiﬁcantly reduced, while the
mRNA expression of glycogen synthase kinase 3b (GSK3b) and tissue inhibitor of
metalloproteinase-2 (TIMP-2) was markedly increased in the TU group. TU treatment
also signiﬁcantly reduced caspase-3 expression.
Conclusions: Different doses of testosterone suppressed ventricular remodeling and
improved left ventricular function, reduced apoptosis, and prevented mortality in a
CHF rat model.
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Effectiveness and Safety of Digoxin on Chronic Heart Failure - Meta Analysis of
Cohort Studies
Yao Jialu, Ya-Feng Zhou
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Objectives: Digoxin has been used for more than 200 years to treat patients with heart
failure (HF), however, there have been inconsistent ﬁndings on the association
between digoxin use and risk of death and heart failure hospitalization. Therefore, we
conduct a meta-analysis of cohort studies to assess the relationship between digoxin
use and the risk of death and heart failure hospitalization.
Methods:We searched the MEDLINE, Embase, CNKI (Chinese National Knowledge
Infrastructure) from January 1993 through October 2013 and reference lists of
retrieved articles, with the use of a standardized protocol which was registered in the
University of York Center for Reviews and Dissemination, the number is:
CRD42013006258. Two authors performed independent article review and study
quality assessment using the Newcastle-Ottawa Scale (NOS) checklist. A random-
effects model was used to calculate the overall combined risk estimates.
Results: Nine cohort studies involving 84, 692 participants were included in the meta-
analysis. The overall combined hazard risks with digoxin use compared with the
reference group were 1.149 (95% CI 1.043-1.266) for all-cause mortality, 1.059 (95%
CI 0.784-1.431) for heart failure hospitalization, 0.988 (95% CI 0.720-1.354) for all-
cause hospitalization. Sensitivity analysis of exclusion of any single study did not
materially alter the overall result. A little evidence of publication bias was observed.
Conclusions: This meta-analysis of cohort studies suggests that digoxin use signiﬁ-
cantly increases the risk of all-cause mortality, and has no effect on heart failure
hospitalization and all-cause hospitalization.
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Left atrial ejection force is independent of left atrial volume in heart failure
patients
Lauren S. Valera, Marcellus Francis Ramirez, Crismelita Banez
University of Santo Tomas HospitalJACC Vol 64/16/Suppl C j October 16–19, 2014 j GW-ICC Abstracts/CObjectives: This study aimed at determining the correlation of left atrial ejection force
(LAEF) and left atrial volume in patients with heart failure.
Methods: This was a prospective cross sectional study done at the University of Santo
Tomas Hospital from October-December 2013. LAEF was computed using the
modiﬁed Manning’s Method. The left atrial volume was measured using the bi-plane
method. Correlation between the variables were analysed using the Pearson’s R.
Results: Thirty six patients were enrolled (22 males, 14 females). Mean age was
64.3613.23. The mean computed LAEF was increased at 16.611.6 kdynes. The
mean age corrected LAEF was increased at 287.83197 kdynes. Age and left atrial
volume were not signiﬁcantly correlated with computed LAEF and age corrected
LAEF (P value 0.121, 0.367, 0.187, 0.661). Only peak A velocity was found to be
signiﬁcantly correlated with computed (value 0.001) and age corrected LAEF (value
0.001).
Conclusions: LAEF was increased in patients with heart failure. Peak A velocity was
correlated with computed and age corrected LAEF. Hence, Peak A velocity maybe
used as a marker of overall left atrial function.
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Clinical signiﬁcance of red blood cell distribution width in patients with
heart failure
Xu Haikun, Yang Ping
China-Japan Union Hospital of Jilin University
Objectives: Heart failure (HF) is one of the global public health problems which have
important inﬂuence on human health. Red blood cell distribution width (RDW) is a
measure of the variability in the size of circulating erythrocytes. In recent years, more
and more studies have shown that RDW is a risk stratiﬁcation and powerful prognostic
indicator for patients with heart failure. In this study, we compared the RDW with the
already known heart failure marker to analysis the important value of RDW in heart
failure severity and prognosis.
Methods: We retrospectively investigated consecutive patients who visited the car-
diology department of China-Japan Union Hospital from January to June in 2013.
According to the inclusion and exclusion criteria, a total of 240 heart failure patients
were enrolled in the case group. There are each 80 patients in the NYHA II, NYHA III
and NYHA IV group. We selected 200 patients without heart failure as the control
group.For each patient, detailed records of the patient’s information. And fasting
blood taken after admission of all enrolled patients to measured serum creatinine,
blood urea nitrogen, brain natriuretic peptide, and left ventricular ejection fraction
(LVEF) was measured with echocardiography.
Results: Compared with the control group, RDW level was signiﬁcantly higher in the
heart failure group (P<0.001). The RDW level was increased as the NYHA classi-
ﬁcation grade. There is a correlation between RDW and LVEF as well as log
[NT-proBNP], the RDW was signiﬁcantly positive correlated with LVEF (r¼-0.481,
P<0.05) and negative correlated with log[NT-proBNP] (r¼0.0637, P<0.001). The
RDW level, LVEF, eGFR and log [NT-proBNP] was signiﬁcantly different between
the cardiovascular events group and non-events group, and the COX regression
analysis showed that RDW and Log [NT-BNP] are independent factors affecting the
cardiovascular events. ROC analysis showed that there is no signiﬁcant different
between the RDW and Log [NT-proBNP] when using the Z test to measure the area
under the curve (P>0.05). While when using the Kaplan-Meier survival curve anal-
ysis, select RDW13.85% as cutoff to compare for the survival time of readmission, the
incidence of cardiovascular events. Signiﬁcant differences was found between all
these groups (P<0.001); RDW quartile grouped by comparing survival time increased
with RDW, gradually shortened survival time, a signiﬁcant difference (P<0.001)
between the survival curves.
When using quartile grouped methods to compare the cardiovascular events in each
group, we found that at the Q2 stage the RDW is more effective to predict all the
cardiovascular events compared with log [NT-proBNP].
Conclusions: RDW is signiﬁcantly higher in patients with heart failure, and is
signiﬁcantly elevated with NYHA class severity. RDW is negatively correlated with
LVEF, and is positively correlated with log [NT-proBNP]. Therefore, RDW may act
as an important indicator to determine the severity of the patient and as a powerful
prognostic marker to evaluate the cardiovascular events in heart failure patients.
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Effect of Levosimendan on patients with decompensated heart failure
Ma Xiaoju, Yu Shujie, Song Zhiming
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Objectives: To explore the effect of levosimendan on patients with decompensated
heart failure (DHF) and summarize the key points of nursing.
Methods: Eighty-six patients with DHF were randomly divided into levosimendan
group (n¼43) and control group (n¼43). Patients in control group received the
conventional treatment including diuretics, ACE inhibitors, beta-blockers, aldosterone
antagonists and digitalis, while patients in levosimendan group received an extra
intravenous administration of levosimendan for 24 hours. Echocardiography, level of
amino-terminal pro-brain natriuretic peptide (NT-pro BNP), blood pressure (BP),
heart rate (HR) and blood electrolytes were detected and compared. The changes of
symptoms including dyspnea and leg swelling, and adverse events were recorded.
Results: Compared with control group, there were a signiﬁcant increase in SV
[(62.7223.21) ml vs (71.1223.76) ml] and a signiﬁcant decrease in NT-pro BNPardiovascular Disease Clinical Research C183
level [(4542.49561.08) pg/ml vs (4035.11432.65) pg/ml] in levosimendan group
24 hours after treatment. Much more improvement in dyspnea and leg swelling was
seen in levosimendan group 48 hours after treatment. Heart rate was lower in levo-
simendan group [(737.4) bpm vs (878.1) bpm] (P<0.05). However, some adverse
events occurred in levosimendan group and the total incidence of them was 14%
(7 cases with hypotention, 3 cases with headache and 2 cases with hypokalemia).
Conclusions: In patients with DHF, intravenous levosimendan increased the force of
cardiac contraction and provided rapid symptomatic relief. Levosimendan also
increased the risk of adverse events. In order to decrease the adverse events related
harm to the patients caused by levosimendan, nursing management may be of great
value during the treatment. Especially in the ﬁrst several hours of levosimendan
treatment, adverse events should be monitored carefully. Once adverse events occur or
symptoms get worse, they must be immediatly reported to the doctors to adjust the
treatment.
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Correlation of anemia and renal insufﬁciency, Neurohormonal Cytokines
In Elderly Patients With Congestive Heart Failure and effects on
ventricular remodeling
Xi Aiqi, Zhong Xin
The People’s Hospital of Qinghai Province, Xining, Qinghai, Chine
Objectives: To investigate associations among anemia and renal insufﬁciency,
Neurohormonal Cytokines Activation in Elderly patients with congestive heart failure
(CHF), and study their inﬂuence on left ventricular mass index (LVMI), mean wall
stress (MWS) and cardiac function.
Methods: 121 CHF patients were divided into the anemic group (n¼47) and the non-
anemic group (n¼74), Hb concentration, renal function, serum tumor necrosis factor-a
(TNF-a), soluble intercellular adhesion molecule-1 (sICAM-1), interleukin-1 (IL-6),
AngiotensinII (AngII) were measured. left ventricular ejection fraction (LVEF), LVMI
and MWS were measured by echocardiography.
Results: Hb concentration signiﬁcantly decreased, and the level of BUN, Cr increased
with deterioration of cardiac function in CHF patients. 38.8% of patients had anemia,
and 24% had renal insufﬁciency. the anemia and renal insufﬁciency aggravated with
decreaseing LVEF. TNF-a, sICAM-1, IL-6, AngII levels, LVMI and MWS were
higher in the anemic patient group than those in the non- anemic subject group
[(92.336.39) vs (55.6310.16) ng/L, (253.5825.96) vs (237.1833.26) ug/L,
(145.2213.53) vs (106.520.36) ug/L, (144.5364.12) vs (76.6948.49) pg/ml,
(187.78.5 ) vs (108.49.3) g/m2 and (481.125.8) vs (361.823.1) dynes103/
cm2, all P<0.01 respectively]. LVEF was signiﬁcantly decreased in the anemic patient
group compared with that in the non- anemic subject group[(33.945.23) vs
(45.358.82) P<0.01], With the increased with the severity of anemia, the levels of
TNF-a, sICAM-1, IL-6, AngII, LVMI and MWS signiﬁcantly increased; there were
positive correlation between LVMI, MWS and TNF-a, sICAM-1, IL-6, AngII levels
(P<0.01), and a negative correlation between TNF-a, sICAM-1, IL-6, AngII, LVMI,
MWS and Hb concentration (P<0.01).
Conclusions: Neurohormonal and Cytokines Activation play roles in pathophysio-
logical and pathogenetic mechanism of the severity of ventricular remodeling and
anemia, and the occurrence of anemia aggravates the change of ventricular remodeling
in CHF.
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Does alpha-1 blocker provide additional therapeutic beneﬁts in multifactor
acute heart failure patients? -a multi-center randomized and parallel-control
trial between urapidil and nitroglycerin in Chinese elderly patients with DM
and hypertension
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Objectives: To evaluate whether alpha-1blocker provide additional therapeutic ben-
eﬁts than other traditional medications which are currently employed in clinical
setting, the safety and efﬁcacy of urapidil and nitroglycerin on the treatment of elderly
HF patients with hypertension and DM is investigated in a multi-center randomized
and parallel-control trial study.
Methods: 72 elderly patients were randomized into two groups with urapidil (n¼35;
M/F¼19/16) or nitroglycerin (n¼37; M/F¼20/17) treatment. Urapidil and nitroglyc-
erin are deployed with microinfusion pump with the following concentrationC184 JACC Vol 64/16/Suppl C j October 16–1respectively: 50-300 mg / min (urapidil) and 5-20 mg /kg/min (nitroglycerin). Depot
time for both of the drugs is adjusted according to individual clinical setting and lasts
for about 48-140 hours. Blood pressure (BP), heart rate (HR), metabolic panel and
cardiovascular function (NT-proBNP, EF, LVCO, LVEDV, ect.) are measured before
and after the treatment (0 hour, 24 hours, 48 hours, 72 hours and 7 days).
Results: Patients with urapidil exerted signiﬁcantly lower systolic blood pressure
(SBP) than their counterparts in the nitroglycerin group. Moreover, urapidil effectively
ameliorated the NT-proBNP level after treatment. In urapidil treatment group, EF, CI
and LEDV patients were signiﬁcantly improved compared to the patients with
nitroglycerin treatment. Both of these two drugs caused a decrease of fasting plasma
glucose (FPG). But, there was no signiﬁcant difference in FPG of patients between
urapidil- and nitroglycerin-treated groups.
Conclusions: Urapidil had better efﬁcacy than nitroglycerin on lowering and stabi-
lizing the SBP in elderly patients, attenuating the afterload and improving the cardiac
function by affecting the EF, LEDV. Like nitroglycerin, Urapidil signiﬁcantly reduced
the FPG of HF patients with DM without causing adverse effects on metabolic proﬁle
in these patients. While offering an effective way for handling BP of multifactor HF
patients who are complicated with hypertension and DM, Urapidil may provide
additional therapeutic beneﬁts to these patients. Urapidil may be another ﬁrst-line
medication in terms of its mild side effects.
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Clinical Trial of Autologous Bone Mesenchymal cell Transplantation for Severe
heart failure due to Dilated Cardiomyopathy
Meng Zili1,2, Zhen-Ya Sheng2, Hui Li1, Yun-Sheng Yu2, Xiao-Mei Teng2, Zili Meng1,2
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Objectives: Experimental data have suggested that Bone Mesenchymal cell (MSC )
may contribute to the healing of myocardial infarction (MI). We also have certiﬁed
that MSC is effective in treating DCM, for this reason, we treat one dialated car-
diomyopathy (DCM) patient with autologous BMCs.
Methods: One dialated cardiomyopathy (DCM) with heart failure patient were
transplanted with autologous BMCs via the coronary artery. The ejection fraction (EF)
was assessed by echocardiography before and 4, 8, 17, 21, 30, 60 days after MSC
transplantation.
Results: The MSC Transplantation had signiﬁcant sustained improvements in left
ventricular ejection fraction from before transplant (0.26), to 4, 8, 17, 21, 30, 60 days
after cell implantation (0.57, 0.52, 0.55, 0.53, 0.51, 0.45 respectively).
Conclusions: Our data demonstrate that intracoronary transplantation of autologous
BMCs improved cardiac function in DCM patient with a markedly greater improve-
ment. This approach opens a new window in the treatment of ‘no hope’ patients with
congestive heart failure.
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Analysis on the inﬂuence factors of perioperative heart failure in patients with
acute STEMI undergoing emergency PCI
Ma Jianghong, Yang Ping
China-Japan Union hospital of Ji Lin University
Objectives: To analysis the related factors of perioperative heart failure in patients
with acute STEMI undergoing emergency PCI.
Methods: The study involves 227 patients who suffered the ﬁrst acute STEMI and
accepted the treatment of emergency PCI. Record the general information of all
patients including age, gender, the history of hypertension, diabetes, high cholesterol
and smoking, the pain to balloon time, the site of myocardial infarction and the infarct
related coronary artery and whether with multi vessel disease. Record the use of
thrombus aspiration and tiroﬁban and the postoperative TIMI grade of blood ﬂow and
the. Record the speciﬁc numerical about WBC, the percentage of neutrophils, neu-
trophils to lymphocytes ratio (NLR) and mean platelet volume (MPV).Within 2 hours
after PCI again for the 12 lead ECG and record the level of ST resolution (STR)
compared with the ECG before PCI. Deﬁned the STR 50% and the STR >50%.
Record LVEF according to the cardiac ultrasound echocardiography one week after
PCI. Deﬁne LVEF 45% as heart failure group and LVEF>45% as the non heart
failure group. All the data were analyzed by statistical software SPSS17.0. The dif-
ference was statistically signiﬁcant when P<0.05.
Results: Compared with the non heart failure group, in heart failure group, the
average age (61.0812.62 vs 57.6610.78) is bigger, the average time of chest pain
to balloon (5.413.24 vs 4.412.80) is longer, the proportion of the anterior
descending branch as the infarct related coronary artery (65% vs 48%) is higher, the
proportion of the anterior wall as the site of myocardial infarction (60% vs 35%) is
higher, the proportion of using the tiroﬁban (24% vs 38%) is lower, the proportion of
postoperative TIMI grade of blood ﬂow <3 (11% vs 3%) is higher, the total number of
WBC (11.433.05 vs 10.483.02) is bigger, the percentage of neutrophils
(82.208.16 vs 73.5813.45) is higher, the NLR (8.664.13 vs 5.253.47) is
higher, and there were statistically signiﬁcant differences between the two groups
(P<0.05). Multi factor regression analysis showed that STR  50% 2 hours after PCI
and long time of chest pain to balloon are two relatively independent risk factors of
heart failure during perioperative period of emergency PCI. Linear correlation analysis
showed that the age (r¼-0.190, P¼0.004), the total number of WBC (r¼-0.134,9, 2014 j GW-ICC Abstracts/Cardiovascular Disease Clinical Research
